Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Claritin/Singulair; Montelukast/loratadine

Latest Information Update: 22 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough/Merck Pharmaceuticals
  • Class Acetates; Antiallergics; Antiasthmatics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Quinolines
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 27 Jun 2008 Schering-Plough/Merck Pharmaceuticals withdraws NDA for loratadine/montelukast in Seasonal allergic rhinitis
  • 25 Apr 2008 Schering-Plough/Merck Pharmaceuticals receives non-approvable letter from the FDA for loratadine/montelukast in Seasonal allergic rhinitis
  • 30 Aug 2007 Preregistration for Seasonal allergic rhinitis in USA (PO), FDA has accepted filing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top